Universities Allied for Essential Medicines (UAEM) Conference at Yale

1. Universities Allied for Essential Medicines (UAEM) Conference at Yale The Health Impact Fund: Pharmaceutical Innovation also for the Poor Thomas Pogge Leitner Professor of Philosophy and International Affairs, Yale University with additional affiliations at the Australian Centre for Applied Philosophy and Public Ethics (CAPPE) and the University of Oslo Centre for the Study of Mind in Nature (CSMN)

2. Rules Governing the Development and Distribution of New Medicines Under the TRIPS agreement – part of the WTO Treaty and a paradigm example of regulatory capture – the intellectual property regime of the affluent countries was globalized by being made a mandatory condition of WTO membership. Pharmaceutical innovators must be granted 20-year product patents in all WTO member states.

3. Seven Problems with TRIPS-Pure 1. High prices impeding access by the poor 2. Neglected diseases (90/10 Problem) 3. Bias toward maintenance drugs 4. Patenting, litigation, deadweight losses 5. Cost-price differential  counterfeiting 6. Cost-price diff’l  excessive marketing 7. Last-mile problem, perverse incentives

4. Global Pharmaceutical Demand Curve

5. When is an Institutional Regime Human-Rights-Violating? If and only if the following four conditions all hold: The institutional order is associated with a massive human-rights deficit among its participants. This association is reasonably avoidable through some alternative design of that institutional order. The association in (1) is foreseeable. Its avoidability (2) is also foreseeable: We can know that the alternative institutional design would do much better in terms of giving participants secure access to the objects of their human rights. 4

6. Human Rights as Moral Claims on (Global) Institutional Arrangements “Everyone is entitled to a social and international order in which the rights and freedoms set forth in this Declaration can be fully realized” (Article 28) Universal Declaration of Human Rights, 1948 5

7. We Should Focus Our Political Efforts on a Reform that ― constitutes an enduring structural reform; ― effectively symbolizes the idea that all human lives are of equal value; ― benefits a strong, well-organized faction of the global elite (new profit opportunities and image improvement for pharma industry); ― is scalable and can be increased and/or adjusted as experience warrants; ― strengthens those with objective interest in reform (empowerment of the global poor); ― is exemplar of realistic moral leadership, genuine moralization, global public good. 6

8. 2 The Health Impact Fund: Rewarding Innovation without Obstructing Access by the Poor

9. The Economics of Drug Development Estimates of average drug R&D costs are in the hundreds of millions of dollars About half of this cost relates to clinical trials (mainly phase 3). Any solution must address the need to pay for these costs (including for failed R&D efforts), and must create incentives for firms to invest in R&D including clinical trials. 8

10. The Health Impact Fund (HIF) Funded by willing governments at minimally $6 billion per annum (0.01% of GNI, if universal) Promises to reward (upon registration) any new medicine on the basis of its global health impact Registering a new medicine with the HIF is voluntary for the innovator, who need not give up any intellectual property rights Registrant must agree to make the new medicine available wherever it is needed at the lowest feasible cost of manufacture and distribution and to grant zero-priced licenses after reward period www.HealthImpactFund.org 9

11. Financing $6 billion a year is about 0.01% of global income, not even 1% of current worldwide expenditures on pharmaceuticals. Full incentive effects on potential innovators require long-term commitment by funders. Only governments (of affluent and developing countries) can plausibly commit large sums long-term. We propose a small share of GNI, perhaps 0.03%, for each partner country. All or most of this comes back to taxpayers through lower prices for medicines, insurance, national health systems, and foreign aid. 10

13. HIF Resolves Three Critical Problems in Prize Determination Which health problems to target; How to define the “finish line”; How large to make the reward (self-adjusting). The HIF is a market-based solution: payments are determined by competition among all registered products for the available rewards. A drug for malaria can directly compete against a drug for HIV/AIDS. This regulates relative rewards for registered products, rewarding each at the same rate per QALY, creating efficient incentives. 12

14. How to Constrain the Selling Price Three design options: The HIF sets a price ceiling equal to estimated average cost of production The HIF requires open licensing of all relevant patents and data to create generic competition The HIF requires the registrant to issue tenders for production; registrant controls distribution but must sell product at no more than cost of acquisition plus a supplement to cover distribution Cost of production and distribution is to be minimized and registrant is not to profit from selling the drug, only from HIF-rewards. Incentive to lower price iff δQ(R+p–c) > Qδp 13

16. Distribution of Pharma Research Diseases accounting for 90% of the global disease burden receive only 10% of all medical research worldwide. Pneumonia, diarrhea, tuberculosis and malaria, which account for over 20% of the global burden of disease, receive less than 1% of all public and private funds devoted to health research. Of the 1556 new drugs approved between 1975 and 2004, only 18 were for tropical diseases and 3 for TB.

17. How to Assess Health Impact Health impact is to be assessed in QALYs through comparison to outcomes that could have been expected to occur given the state of technology two years before the drug was introduced, and excluding the firm’s own products. Quality-Adjusted Life Years: All health states are rated on a 0-1 scale. 2 QALYs = two extra years in good (1.0) health = four extra years in poor (0.5) health = ten years in improved (+0.2) health. 16

18. How to Assess Health Impact Health impact is to be assessed annually based on available information and inference Assessment will rely on data from Clinical trials Pragmatic or practical trials Audited data on sales aided by serial numbers on packages and mobile phone technology Stratified sampling of use of the product in different environments Global burden of disease data 17

19. Assessment Cost The assessments would be expensive to run, consuming probably about 10% of the fund payout, or $600 million per year. Judged to be feasible by experts (IHME) Better health impact monitoring is a priority in almost all countries already. Clinical reasons Budgetary reasons Assessment costs are therefore partly balanced by collateral benefits. 18

20. Allocation Rules Because pharmaceutical companies negotiate under a virtual veil of ignorance with respect to as yet uninvented medicines, their collective interests will shape their negotiating strategy. They will want to design the allocation rules so as to maximize their collective harvest of rewards. In particular, they will want these rules to be clear and transparent so as to reduce uncertainty. They will want the incentives to be shaped so as to foster efficient collaboration and synergies among themselves. They will want to set up a cheap and reliable arbitration mechanism so as to avoid costly disputes. 19

21. The “Last Mile” Problem in Drug Delivery Proper prescribing and compliance are essential to drug effectiveness. The HIF pays on the basis of each medicine’s actual health impact as assessed not only through sales data, but also through sampling of actual use and benefits as well as through population health data. Firms therefore have incentives to promote appropriate use of their registered products, as well as to develop products that are effective in resource-poor settings. 20

22. Problems Solved? 1. Price = lowest feasible variable cost 2. Diseases of the poor become profitable 3. No bias toward maintenance drugs 4. Patenting, litigation, deadweight losses 5. No cost-price differential: counterfeiting 6. No cost-price differential: marketing 7. Last-mile problem, wholesome incentives